한국인에 있어서 알렌드로네이트 제제의 제형간 유효성 및 순응도 비교

다국어 초록 (Multilingual Abstract)

Alendronate is a bisphosphonate that selectively inhibits osteoclast-mediated bone resorption. Dosing convenience is animportant element for the enhancement of patient compliance and the effective management of osteoporosis. The pur-pose of this study was to compare the effectiveness and compliance among alendronate pharmaceutical products(oralonce-weekly alendronate 70mg, daily alendronate 10mg, and once-weekly alendronate 70mg with Vitamin D3 2800IU) in terms of the change in bone mineral density (BMD), biochemical markers, and compliance estimates. A retro-spective chart review was conducted in patients with osteoporosis who received alendronate 70mg (Group 1), alendr-onate 10 mg (Group 2), or alendronate 70mg with Vitamin D3 2800 IU (Group 3) at the endocrinology department ofa hospital in Korea from Jan. 1, 1998 to Mar. 31, 2008. The primary endpoints were the increases in spine antero-pos-terior BMD T-score and femur trochanter BMD T-score, and the compliance of alendronate products. Secondary end-points included changes in bone turnover-related biochemical markers including bone-specific alkaline phosphatase,urinary N-terminal telopeptides (NTX) and osteocalcin, and in serum vitamin D3 concentration. There was no statisticaldifference in the BMD increase among the three alendronate products; spine BMD T-score increased by 0.49±0.52,0.39±0.48 and 0.50±0.41, and femur trochanter BMD T-score by 0.29±0.42, 0.21±0.53 and 0.24±0.22 in Group 1, 2 and3, respectively. With respect to the increases in femur trochanter BMD T-score and the decreases in NTX and osteocal-cin, 70mg once-weekly group was remarkably superior to 10mg daily group (p<0.05) The compliance of 70mgonce-weekly group was significantly higher than that of 10mg daily treatment group (p<0.001). In conclusion, allthree alendronate treatment groups were equivalent in effectiveness, and the compliance of 70 mg once-weekly groupwas better than that of 10 mg daily treatment group.

목차 (Table of Contents)

• abstract
• 연구 방법
• 연구결과
• 고찰 및 결론
• 참고문헌

참고문헌 (Reference)

1 Barrett-Connor E, "The economic and human costs of osteoporotic fracture" 98 : 3-8, 1995

2 Kanis JA, "The burden of osteoporotic fractures: a method for setting intervention thresholds" 12 : 417-427, 2001

3 Porras AG, "Pharmacokinetics of alendronate" 36 : 315-328, 1999

4 Grazio S, "Persistence of weekly alendronate: a real-world study in Croatia" 27 : 651-653, 2008

5 Poole KE, "Osteoporosis and its management" 333 : 1251-1256, 2006

6 Akesson K, "New approaches to pharmacological treatment of osteoporosis" 81 : 657-664, 2003

7 Marshall D, "Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures" 312 : 1254-1259, 1996

8 2006 position statement of The North Ame, "Management of osteoporosis in postmenopausal women" 13 : 340-367, 2006

9 Hochberg MC, "Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group" 42 : 1246-1254, 1999

10 de Groen PC, "Esophagitis associated with the use of alendronate" 335 : 1016-1021, 1996

11 Peter CP, "Esophageal irritation due to alendronate sodium tablets: possible mechanisms" 43 : 1998-2002, 1998

12 "Consensus development conference. prophylaxis and treatment of osteoporosis" 1 : 114-117, 1991

13 Garnero P, "Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment" 79 : 1693-1700, 1994

14 Hochberg MC, "Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents" 87 : 1586-1592, 2002

15 Bauer DC, "Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial" 19 : 1250-1258, 2004

16 Wasnich RD, "Antifracture efficacy of antiresorptive agents are related to changes in bone density" 85 : 231-236, 2000

17 Chesnut CH, "Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling" 99 : 144-152, 1995